Click on the links below to view abstracts and posters presented at this congress. All copyright remains that of the copyright holder. This page will be available for a limited period after the congress.
Oral presentation 52 Lingvay
Once-weekly semaglutide vs. canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
View PDF
Poster presentation 773 Viljoen
Efficacy and safety of semaglutide by baseline BMI in SUSTAIN 1–5 and 7
View PDF
Oral presentation 53 Capehorn
Efficacy and safety of semaglutide 1.0 mg once weekly vs. liraglutide 1.2 mg once daily as add-on to 1–3 oral glucose-lowering drugs in subjects with type 2 diabetes (SUSTAIN 10)
View PDF
Poster presentation 775 Pratley
Efficacy and safety of once-weekly semaglutide low dose 0.5 mg vs. once-weekly dulaglutide high dose 1.5 mg in type 2 diabetes: a post hoc analysis of SUSTAIN 7
View PDF
Oral presentation 54 McCrimmon
Effects of once-weekly semaglutide vs. canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial
View PDF
Poster presentation 776 Ludvik
Efficacy and safety of semaglutide by background sodium-glucose cotransporter-2 inhibitor: a post hoc analysis of SUSTAIN 9
View PDF
Poster presentation 754 Wilding
Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction
View PDF
Poster presentation 821 Löndahl
Cost-effectiveness of once-weekly semaglutide versus empagliflozin in people with type 2 diabetes and inadequate glycaemic control in Sweden
View PDF
Poster presentation 757 Bain
The effect of once-weekly semaglutide on MACE, blood pressure and lipids by race and ethnicity: a SUSTAIN 6 post hoc analysiss
View PDF